T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

T-Cell Metabolism, Immunodeficiency and Human Disease

Adoptive T Cell Therapy Applications

CAR-T Cell Toxicity and Safety Profiles

New discovery challenges a decades-old assumption in HIV biology

Researchers from Queen Mary University of London have uncovered a previously unknown mechanism by which HIV-1 can infect resting immune cells.

6 May 2026

USF researchers develop AI framework to predict immune system responses

Artificial intelligence is increasingly being used to help scientists accelerate drug discovery and search for new treatments.

6 May 2026

New CAR T cell design boosts persistence and reduces toxicity

CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting benefit – often because the infused cells fail to expand or persist.

30 Apr 2026

Maternal screening could help prevent deadly forms of leukemia

A deadly form of leukemia may be stopped before it ever develops by introducing targeted maternal screening in the United States, according to new research.

30 Apr 2026

Multiple myeloma mortality rates decline with advances in targeted therapies

A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023."

29 Apr 2026

Why H2N2 flu is back on the pandemic preparedness radar

A historical review in Vaccine warns that global H2N2 immunity has sharply declined since the 1957 Asian influenza pandemic, leaving most people without H2-specific protection if the virus re-emerges. The authors highlight animal reservoirs, waning birth-cohort immunity, and modern H2 vaccine platforms as key priorities for pandemic preparedness.

28 Apr 2026

Obesity may leave immune cells stuck in inflammatory mode after weight loss

A new EMBO Reports study suggests that obesity can leave a lasting epigenetic imprint on CD4 T cells, delaying the restoration of adaptive immune balance after weight loss. Using mouse models and human cohorts, researchers linked this immune “memory” to DNA methylation changes, saturated fatty acids, autophagy, and immune senescence.

28 Apr 2026

Researchers uncover new mechanism linking metabolism, immunity, and skeletal health

Obesity alters bone health not only through increased body weight but also by reshaping the bone marrow environment.

25 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026

Targeting glutamine metabolism enhances CAR-macrophage cancer therapy

Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) exhibit significant metabolic dysregulation, which impairs their antitumor function.

20 Apr 2026

Antiretroviral therapy reduces biological aging in people living with HIV

A major study presented today at ESCMID Global 2026 has found that antiretroviral therapy (ART) reduces accelerated biological ageing in people with HIV (PWH) by nearly four years, a finding that could transform how clinicians monitor HIV treatment and long-term health outcomes.

20 Apr 2026

Scientists find unexpected immune pathways for mRNA cancer vaccines

The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic.

17 Apr 2026

Mitochondrial activity keeps dendritic cells ready to fight disease

Researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) show that active mitochondria maintain dendritic cells, the immune system's sentinels, in a "ready-to-respond" state, linking cellular metabolism to gene regulation and T-cell activation.

15 Apr 2026

Damon Runyon supports young scientists driving cancer research innovation

The Damon Runyon Cancer Research Foundation has named 13 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

11 Apr 2026

Precision medicine tools offer hope for patients with rare blood cancers

Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.

9 Apr 2026

OICR funds four Ontario teams to develop next-generation cancer therapies

Better cancer care depends on better treatment options. That's why the Ontario Institute for Cancer Research (OICR) is supporting four Ontario-based research teams working to develop the next generation of cancer therapies that are designed to be more effective at destroying tumors, have reduced side effects, and make cancer less likely to return.

9 Apr 2026

Clusterin inhibition offers new hope for treating cervical gastric-type adenocarcinoma

Gastric-type adenocarcinoma (GAS) is one of the most aggressive non-human papillomavirus (HPV)-associated cervical adenocarcinomas and remains especially difficult to diagnose and treat.

8 Apr 2026

State-run insurance plans for foster kids leave some of them without doctors

Ollie Super has moved in and out of cancer treatment since she was diagnosed with neuroblastoma as a toddler in foster care. Now 8, the second grader is dealing with it again. Her cancer came back late last year.

2 Apr 2026

NCCN conference highlights advances in global cancer care strategies

The National Comprehensive Cancer Network® (NCCN®)-a non-profit alliance of leading cancer centers-brought together more than a thousand oncology professionals at the NCCN 2026 Annual Conference in Orlando, Florida, with hundreds more joining virtually.

1 Apr 2026